தேசிய அடிப்படை மருத்துவ காப்பீடு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from தேசிய அடிப்படை மருத்துவ காப்பீடு. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In தேசிய அடிப்படை மருத்துவ காப்பீடு Today - Breaking & Trending Today

China lists COVID-19 medicines in health insurance directory

China lists COVID-19 medicines in health insurance directory
Source: Global Times Published: 2020/12/28 18:06:26
A medical staff member informs residents of the dos and don ts for COVID-19 tests at the Pidu District Hospital of Traditional Chinese Medicine in Pidu District of Chengdu, capital of southwest China s Sichuan Province, Dec. 10, 2020. Chengdu reported zero increase in new domestically transmitted COVID-19 cases and asymptomatic cases from 9 p.m. Tuesday to 6 p.m. Wednesday, while citywide nucleic acid tests are continuing, local authorities said. At the Pidu District Hospital of Traditional Chinese Medicine, medical workers have been working 24 hours nonstop to conduct COVID-19 tests as quickly as possible. (Xinhua/Shen Bohan) ....

Xinhua Shen Bohan , National Basic Medical Insurance , National Health Security Administration , China Healthcare Security Administration , China Ministry Of Human Resources , National People Congress , Pidu District Hospital , Traditional Chinese Medicine , Pidu District , Sichuan Province , Shen Bohan , Human Resources , Social Security , Work Related Injury Insurance , Maternity Insurance , National Health Security , National People , Healthcare Security Administration , தேசிய அடிப்படை மருத்துவ காப்பீடு , சீனா அமைச்சகம் ஆஃப் மனிதன் வளங்கள் , தேசிய மக்கள் காங்கிரஸ் , பாரம்பரிய சீன மருந்து , ஸிச்வாந் மாகாணம் , ஷென் போஹன் , மனிதன் வளங்கள் , சமூக பாதுகாப்பு ,

Uni-Bio Science Group: The National Medical Products Administration Granted Marketing Approval for BOSHUTAI® (Acarbose Tablets) in China

®. Next step, the Company will focus on the launch and successful commercialization of BOSHUTAI
®. As manufacturing cost leadership is essential for the success of the product, the company is already working with a number of strategic partnerships across the supply chain to ensure BOSHUTAI
® is manufactured at the lowest cost possible. Additionally, the Company successfully held the BOSHUTAI
® launch conference on 11 December 2020, where more than 60 commercial partners attended the event.
Acarbose was first developed by Bayer in 1975 and launched in Switzerland in 1986 (trade name: Glucobay
®). As the first FDA-approved alpha-glucosidase inhibitor in the world, it entered China in 1994 and is now recommended as a first-line drug for T2D. Acarbose is sold far better in China and Asia than in other western countries due to the high carbohydrate content in Asian cuisine. ....

Frank Zhao , Xu Honglei , Bio Science Group , Science Group Head , National Essential Medicine List , National Basic Medical Insurance , China National Drug Centralized Procurement Scheme , National Medical Products Administration , Science Group , International Diabetes Federation , Bio Science Group Limited The Company , Bio Science Group Limited , Acarbose Tablets , Yingli Executive Director , Acarbose Market Authorization Holder , Uni Bio Science Group , China Diabetes Prevention , Therapy Guide , National Basic Medical , வெளிப்படையான ழோ , உயிர் அறிவியல் குழு , அறிவியல் குழு தலை , தேசிய அவசியம் மருந்து பட்டியல் , தேசிய அடிப்படை மருத்துவ காப்பீடு , சீனா தேசிய மருந்து மையப்படுத்தப்பட்ட ப்ரொக்யூர்மெஂட் திட்டம் , அறிவியல் குழு ,